Please ensure Javascript is enabled for purposes of website accessibility

Why Global Blood Therapeutics Rocketed Higher Today

By Brian Orelli, PhD - Mar 8, 2017 at 4:17PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

A potential acquisition sends the biotech's shares higher.

What happened

Global Blood Therapeutics (GBT 0.27%) is up 20% at 3:42 p.m. EST after Reuters reported that Novo Nordisk (NVO -0.65%) has approached the biotech about a potential acquisition.

So what

Reuters cites unidentified sources, and both companies declined to comment. Nevertheless, the rumor is probably true. Companies often have their bankers talk to the media to try and push things along.

If the two sides are far apart in price -- or Global Blood Therapeutics isn't willing to negotiate at all -- Novo Nordisk might want investors to know that it's interested in putting pressure on Global Blood Therapeutics. Alternatively, Global Blood could have released the information hoping to spur a higher bid from another company. With the price of insulin decreasing, Novo Nordisk's growth has stalled, and management has said it's interested in licensing products, or making bolt-on acquisitions, giving some validity to the Reuters article.

Global Blood's lead drug candidate, GBT440, which treats sickle cell disease, would fit nicely with Novo Nordisk's hemophilia drugs. The biotech is also testing GBT440 as a treatment for chronic hypoxemic pulmonary disorders, including idiopathic pulmonary fibrosis and acute respiratory distress syndrome. That might be a little outside of Novo Nordisk's wheelhouse, but the company could always partner out that indication if it didn't want to build out a sales force to target pulmonologists.

Sickled red blood cells

Image source: Getty Images.

Now what

While a deal between Global Blood and Novo Nordisk makes sense, there are no guarantees that it'll get done. Investors who buy at this inflated price should buy based on Global Blood's value as a stand-alone company, and treat any additional premium as a bonus if the biotech is purchased.

Brian Orelli has no position in any stocks mentioned. The Motley Fool recommends Novo Nordisk. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Global Blood Therapeutics, Inc. Stock Quote
Global Blood Therapeutics, Inc.
$66.75 (0.27%) $0.18
Novo Nordisk A/S Stock Quote
Novo Nordisk A/S
$107.50 (-0.65%) $0.71

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/12/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.